I3LUNG (101057695)

  https://cordis.europa.eu/project/id/101057695

  Horizon Europe (2021-2027)

  Integrative science, Intelligent data platform for Individualized LUNG cancer care with Immunotherapy

  Data-driven decision-support tools for better health care delivery and policy-making with a focus on cancer (HORIZON-HLTH-2021-CARE-05-02)

  lung cancer  ·  immunotherapy  ·  machine learning

  2022-06-01 Start Date (YY-MM-DD)

  2027-05-31 End Date (YY-MM-DD)

  € 9,996,697


  Description

Immunotherapy (IO) is the new standard of care for many patients with advanced Non-Small Cell Lung Cancer (aNSCLC), yet only around 30-50% of treated patients benefit from IO in the long term. Programmed Death-Ligand 1 (PD-L1) remains the only biomarker used to predict patient outcome to IO, though its efficacy is limited. Other potential biomarkers have been identified, yet not validated in prospective randomized clinical trials, providing only partial evidence. Due to the dynamic complexity of the immune system-tumour microenvironment, its interaction with the host and patient behaviour, it?s unlikely for a single biomarker to accurately predict patient outcome. Artificial Intelligence (AI) and machine learning (ML) frameworks, that synthetize and correlate information from multiple sources, are essential to develop powerful decision-making tools able to deal with this highly complex context and provide individualized predictions to improve patient outcomes reducing the economic burden of health care systems in NSCLC. The aim of the I3LUNG project is to develop such AI-based tools to assist in improving survival and quality of life, preventing undue toxicity, and reducing treatment costs. I3LUNG adopts a two-pronged approach: setting up a transnational platform of available data from 2000 patients in order to validate the AI models, and generating a multi-omics prospective data collection in 200 NSCLC patients integrating diverse -omic information then validate its usefulness in leading IO therapeutic decisions. A psychological study will help in defining the impact of AI-guided decisions on patients, eliciting their preference, and physicians comparing AI with Human Intuition. The final goal is the construction of a novel integrated AI-assisted Data Storage and Elaboration Platform backed up by Trustworthy Explainable AI methodology, ensuring its accessibility and ease of use by healthcare providers and patients alike.


  Complicit Organisations

1 Israeli organisation participates in I3LUNG.

Country Organisation (ID) VAT Number Role Activity Type Total Cost EC Contribution Net EC Contribution
Spain FUNDACIO PRIVADA INSTITUT D'INVESTIGACIO ONCOLOGICA DE VALL-HEBRON (VHIO) (995163935) ESG64384969 participant REC € 891,452 € 891,452 € 891,452
Italy ISTITUTO EUROPEO DI ONCOLOGIA SRL (999969703) IT08691440153 participant PRC € 400,875 € 400,875 € 400,875
Italy ISTITUTO DI RICERCHE FARMACOLOGICHE MARIO NEGRI (999661146) IT03254210150 participant REC € 511,350 € 511,350 € 511,350
Switzerland LUNG CANCER EUROPE LUCE (917199991) CHE291783845MWST associatedPartner OTH € 0 € 0 € 0
Sweden IHE, INSTITUTET FOR HALSO- OCH SJUKVARDSEKONOMI AKTIEBOLAG (920403319) SE556186349801 participant PRC € 229,437 € 229,437 € 229,437
Italy ML CUBE S.R.L. (889667123) IT11482170963 participant PRC € 551,635 € 551,635 € 551,635
Germany LUNGENCLINIC GROSSHANSDORF GMBH (887551650) DE227553468 participant OTH € 397,375 € 397,375 € 397,375
Greece PERSEYS ANONYMOS ETAIREIA EKMETALLEFSIS LEITOYRGEIAS FOREON YGEIONOMIKIS MERIMNAS (952405365) EL099551880 participant PRC € 350,000 € 350,000 € 350,000
United States THE UNIVERSITY OF CHICAGO (993760054) nan participant HES € 1,032,093 € 1,032,093 € 1,032,093
Germany UNIVERSITAETSKLINIKUM HAMBURG-EPPENDORF (999857474) DE218618948 participant HES € 511,250 € 511,250 € 511,250
Italy POLITECNICO DI MILANO (999879881) IT04376620151 participant HES € 1,063,775 € 1,063,775 € 1,063,775
Spain MEDICA SCIENTIA INNOVATION RESEARCH SL (906186126) ESB65778946 participant PRC € 660,275 € 660,275 € 660,275
Israel SHAARE ZEDEK MEDICAL CENTER (925740550) nan participant OTH € 1,149,500 € 1,149,500 € 1,149,500
Belgium KATHOLIEKE UNIVERSITEIT LEUVEN (999991334) BE0419052173 participant HES € 350,500 € 350,500 € 350,500
Italy FONDAZIONE IRCCS ISTITUTO NAZIONALE DEI TUMORI (998538759) IT04376350155 coordinator REC € 1,607,247 € 1,607,247 € 1,607,247
Denmark AALBORG UNIVERSITET (999904034) DK29102384 participant HES € 289,931 € 289,931 € 289,931